RxDoctor Payments Data

Amaryah Yaeger

Acute Care · Philadelphia, PANPI 1003694415

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,207 of the $6,651 with a category attached, or 63.3%. Medtronic accounts for 90.0% of it on its own, with 10 other manufacturers making up the rest. Among acute care clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,651in general payments, 2019–2025

Across 32 payments — averaging $207.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • Boston Scientific$257
  • Biosense Webster, Inc.$127
  • Heartflow, Inc.$103
  • Kiniksa Pharmaceuticals International, PLC$48
  • Abbott$24
  • plus $104 from 5 others

What the payments were for

  • Consulting fees$4,20763%
  • Travel & lodging$1,45222%
  • Food & beverage$99215%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,651 in reported general payments places this provider in the 95th percentile of 872 acute care providers in Pennsylvania.

See all acute care providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$19,288
Medicare patients
162
Services billed
456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban47$47,103
EntrestoSacubitril/Valsartan32$26,050
XareltoRivaroxaban15$24,705
Metoprolol Succinate95$2,048
Spironolactone29$382
Amlodipine Besylate28$265
Rosuvastatin Calcium23$245
Losartan Potassium14$233
Atorvastatin Calcium16$198
Potassium Chloride11$172
Furosemide25$140
Hydrochlorothiazide11$39

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$24$26,05032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 872 acute care providers in Pennsylvania.

Other acute care in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →